• News
  • SAN DIEGO
  • BioTech

Neurocrine nets $9.5 million in 4Q

Neurocrine Biosciences Inc. (Nasdaq: NBIX) Friday announced its net income for the fourth quarter of 2012 rose to $9.5 million or $0.14 per fully diluted share, compared to net income of $1.3 million, or $0.02 per fully diluted share, for the same period in 2011.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Neurocrine Biosciences Inc.

Company Website

12790 El Camino Real
San Diego, CA 92130

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
NBIX
18.95
  0.36  
+ 1.94%
554,669,000
20.29
8.63

Insider Trade Data

Date Insider Shares Type Value
11/17/2014 O Brien, Christopher F 34,537 Sell $655,985
11/17/2014 O Brien, Christopher F 34,537 Exchange $89,451
11/13/2014 O Brien, Christopher F 23,237 Sell $435,522
11/13/2014 O Brien, Christopher F 23,237 Exchange $60,184
11/10/2014 O Brien, Christopher F 20,000 Exchange $51,800

Neurocrine Biosciences Inc. Executive(s):

Kevin Gorman

  • Chief Executive Officer, President

Similar Companies

NAICS - 325412 - Pharmaceutical Preparation Manufacturing
SIC - 2834 - PHARMACEUTICAL PREPARATIONS
SIC - 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
NAICS - 541711 - Research and Development in Biotechnology
SIC - 8733 - NONCOMMERCIAL RESEARCH ORGANIZATIONS
SIC - 8731 - COMMERCIAL PHYSICAL AND BIOLOGICAL RESEARCH
Subscribe Today!